دورية أكاديمية
Microenvironmental Heterogeneity in Brain Malignancies.
العنوان: | Microenvironmental Heterogeneity in Brain Malignancies. |
---|---|
المؤلفون: | Perus LJM; Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, QC, Canada.; Department of Physiology, Faculty of Medicine, McGill University, Montreal, QC, Canada., Walsh LA; Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, QC, Canada.; Department of Human Genetics, Faculty of Medicine, McGill University, Montreal, QC, Canada. |
المصدر: | Frontiers in immunology [Front Immunol] 2019 Oct 01; Vol. 10, pp. 2294. Date of Electronic Publication: 2019 Oct 01 (Print Publication: 2019). |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
اللغة: | English |
بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
مواضيع طبية MeSH: | Biological Variation, Population* , Tumor Microenvironment*, Brain Neoplasms/*diagnosis, Brain Neoplasms/etiology ; Brain Neoplasms/secondary ; Brain Neoplasms/therapy ; Combined Modality Therapy ; Disease Management ; Disease Susceptibility ; Humans ; Neovascularization, Pathologic ; Recurrence |
مستخلص: | Brain tumors are among the deadliest malignancies. The brain tumor microenvironment (TME) hosts a unique collection of cells, soluble factors, and extracellular matrix components that regulate disease evolution of both primary and metastatic brain malignancies. It is established that macrophages and other myeloid cells are abundant in the brain TME and strongly correlate with aggressive phenotypes and distinct genetic signatures, while lymphoid cells are less frequent but are now known to have a pronounced effect on disease progression. Different types of brain tumors vary widely in their microenvironmental contexture, and the proportion of various stromal components impacts tumor biology. Indeed, emerging evidence suggests an intimate link between the molecular signature of tumor cells and the composition of the TME, shedding light on the mechanisms which underlie microenvironmental heterogeneity in brain cancer. In this review, we discuss the association between TME composition and the diverse molecular profiles of primary gliomas and brain metastases. We also discuss the implications of these associations on the efficacy of immunotherapy in brain malignancies. An appreciation for the causes and functional consequences of microenvironmental heterogeneity in brain cancer will be of crucial importance to the rational design of microenvironment-targeted therapies for these deadly diseases. (Copyright © 2019 Perus and Walsh.) |
References: | Cancer Discov. 2015 Nov;5(11):1164-1177. (PMID: 26410082) Cell. 2009 Nov 25;139(5):891-906. (PMID: 19931152) Neuro Oncol. 2017 Oct 19;19(11):1511-1521. (PMID: 28444227) Neurosurgery. 2000 Apr;46(4):957-61; discussion 961-2. (PMID: 10764271) J Neurosci. 2003 Jun 15;23(12):5149-60. (PMID: 12832539) Neoplasia. 2010 Sep;12(9):748-54. (PMID: 20824051) Neuro Oncol. 2018 Oct 9;20(11):1505-1516. (PMID: 29846705) Brain Pathol. 2004 Jul;14(3):237-48. (PMID: 15446578) Neuron. 2002 Jun 13;34(6):945-60. (PMID: 12086642) J Pathol. 2008 Sep;216(1):15-24. (PMID: 18553315) Nature. 2012 Aug 23;488(7412):522-6. (PMID: 22854781) J Clin Oncol. 2009 Oct 1;27(28):4733-40. (PMID: 19720927) Cell Stem Cell. 2014 Mar 6;14(3):357-69. (PMID: 24607407) Nat Med. 2010 Jan;16(1):116-22. (PMID: 20023634) Am J Pathol. 2010 Jun;176(6):2958-71. (PMID: 20382702) Neoplasia. 2011 Mar;13(3):286-98. (PMID: 21390191) Nat Commun. 2019 Apr 16;10(1):1787. (PMID: 30992437) Cell Stem Cell. 2010 Feb 5;6(2):141-52. (PMID: 20144787) Genes Dev. 2017 Apr 15;31(8):774-786. (PMID: 28465358) J Neurooncol. 2014 Mar;117(1):147-52. (PMID: 24469854) J Cell Biol. 2003 Nov 10;163(3):583-95. (PMID: 14610060) Nat Neurosci. 2007 Dec;10(12):1544-53. (PMID: 18026096) Cancer Immunol Res. 2015 Mar;3(3):254-65. (PMID: 25403716) Oncoimmunology. 2018 Jan 16;7(4):e1412909. (PMID: 29632728) Nature. 2015 Nov 5;527(7576):100-104. (PMID: 26479035) Clin Cancer Res. 2011 Mar 15;17(6):1603-15. (PMID: 21135147) Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12550-5. (PMID: 25114226) Cancer Cell. 2014 Aug 11;26(2):288-300. (PMID: 25117714) Nature. 1992 Apr 23;356(6371):713-5. (PMID: 1570015) J Clin Oncol. 2011 Apr 10;29(11):1408-14. (PMID: 20823417) Cancer Cell. 2010 Jan 19;17(1):98-110. (PMID: 20129251) Nat Commun. 2018 Nov 19;9(1):4845. (PMID: 30451869) Cancer Res. 2011 Sep 15;71(18):6061-72. (PMID: 21788346) Nature. 2019 Jan;565(7738):234-239. (PMID: 30568305) Oncotarget. 2015 Jun 20;6(17):15077-94. (PMID: 25987130) J Comp Neurol. 2000 Oct 2;425(4):479-94. (PMID: 10975875) J Clin Oncol. 2013 Jan 20;31(3):337-43. (PMID: 23071247) Neuro Oncol. 2016 Oct;18(10):1402-12. (PMID: 27116977) Cell Stem Cell. 2010 May 7;6(5):421-32. (PMID: 20452317) Science. 2018 May 11;360(6389):660-663. (PMID: 29748285) Nature. 2008 Oct 16;455(7215):971-4. (PMID: 18923524) Immunity. 2019 Jan 15;50(1):253-271.e6. (PMID: 30471926) Science. 2017 Mar 31;355(6332):. (PMID: 28360267) Cell Stem Cell. 2009 May 8;4(5):453-63. (PMID: 19427294) Cancer Res. 2015 Sep 15;75(18):3713-9. (PMID: 26208905) Br J Cancer. 2017 Jun 6;116(12):1558-1563. (PMID: 28524161) Nature. 2010 Jan 21;463(7279):318-25. (PMID: 20032975) Cell. 2015 Jan 15;160(1-2):48-61. (PMID: 25594174) Sci Rep. 2016 Apr 06;6:23834. (PMID: 27048955) Cancer Res. 2013 Jul 1;73(13):3913-26. (PMID: 23636127) Cancer Cell. 2017 Jul 10;32(1):42-56.e6. (PMID: 28697342) Nat Med. 2019 Mar;25(3):470-476. (PMID: 30742120) Nat Genet. 2004 Aug;36(8):827-35. (PMID: 15258583) N Engl J Med. 2005 Mar 10;352(10):997-1003. (PMID: 15758010) Sci Transl Med. 2015 Mar 4;7(277):277ra30. (PMID: 25739764) Nat Methods. 2015 May;12(5):453-7. (PMID: 25822800) Clin Cancer Res. 2008 Dec 15;14(24):8228-35. (PMID: 19088040) Eur J Neurosci. 2003 Apr;17(7):1355-64. (PMID: 12713638) Nature. 2017 Jul 20;547(7663):355-359. (PMID: 28678782) Nat Med. 2019 Mar;25(3):477-486. (PMID: 30742122) Clin Cancer Res. 2016 Feb 1;22(3):582-95. (PMID: 26405194) Cancer Cell. 2007 Jan;11(1):69-82. (PMID: 17222791) J Inherit Metab Dis. 2013 May;36(3):437-49. (PMID: 23609350) Cancer Discov. 2018 Sep;8(9):1069-1086. (PMID: 30115704) Cancer Cell. 2017 Mar 13;31(3):326-341. (PMID: 28292436) Neuro Oncol. 2015 Aug;17(8):1064-75. (PMID: 25355681) Nature. 2009 Dec 10;462(7274):739-44. (PMID: 19935646) Genes Dev. 2008 Feb 15;22(4):436-48. (PMID: 18281460) Nat Rev Neurosci. 2006 Jan;7(1):41-53. (PMID: 16371949) Cancer Discov. 2015 Jun;5(6):610-21. (PMID: 25929848) Nature. 2015 Dec 3;528(7580):93-8. (PMID: 26536111) JAMA Oncol. 2017 Aug 01;3(8):1069-1077. (PMID: 28301662) Elife. 2017 Oct 03;6:. (PMID: 28971799) Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14. (PMID: 23412337) Nat Med. 2013 Oct;19(10):1264-72. (PMID: 24056773) J Biol Chem. 2015 Feb 6;290(6):3814-24. (PMID: 25538243) Clin Neurosurg. 1976;23:440-53. (PMID: 975695) Breast Cancer Res. 2012 Aug 16;14(4):R119. (PMID: 22898337) Cancer Cell. 2012 Oct 16;22(4):425-37. (PMID: 23079654) J Clin Oncol. 2019 Jan 1;37(1):52-60. (PMID: 30407895) Science. 2010 Nov 5;330(6005):841-5. (PMID: 20966214) Cancer Cell. 2013 Sep 9;24(3):331-46. (PMID: 23993863) Clin Cancer Res. 2009 Aug 1;15(15):4829-37. (PMID: 19622585) Cell. 2013 Oct 10;155(2):462-77. (PMID: 24120142) Clin Cancer Res. 2015 Feb 15;21(4):870-81. (PMID: 25492084) N Engl J Med. 2017 Nov 16;377(20):1954-1963. (PMID: 29141164) Cancer Res. 2006 Aug 15;66(16):7843-8. (PMID: 16912155) Genome Biol. 2016 Oct 20;17(1):218. (PMID: 27765066) PLoS One. 2009 Jun 10;4(6):e5857. (PMID: 19516901) Nat Neurosci. 2007 Dec;10(12):1538-43. (PMID: 18026097) Oncotarget. 2015 Oct 6;6(30):29254-67. (PMID: 26299612) Cell. 2016 Jan 28;164(3):550-63. (PMID: 26824661) Nature. 2019 Jan;565(7738):240-245. (PMID: 30568303) N Engl J Med. 2014 Feb 20;370(8):699-708. (PMID: 24552317) Nat Med. 2019 Jun;25(6):1022. (PMID: 30996326) Cell Death Differ. 2012 Mar;19(3):428-39. (PMID: 21836617) Clin Cancer Res. 2010 Dec 1;16(23):5722-33. (PMID: 20921210) JAMA Oncol. 2017 May 01;3(5):666-671. (PMID: 27926948) Br J Neurosurg. 2001 Apr;15(2):101-8. (PMID: 11360371) JCI Insight. 2016;1(2):. (PMID: 26973881) PLoS One. 2012;7(8):e43339. (PMID: 22937035) J Clin Oncol. 2014 Jul 1;32(19):2100-8. (PMID: 24799487) Nature. 2015 Jul 16;523(7560):337-41. (PMID: 26030524) Cancer Res. 2016 Aug 1;76(15):4372-82. (PMID: 27221704) Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7. (PMID: 16916931) Cell. 1990 Nov 16;63(4):835-41. (PMID: 2121369) Cell. 2019 Aug 8;178(4):835-849.e21. (PMID: 31327527) Cell. 1990 Nov 16;63(4):851-9. (PMID: 2121371) Immunity. 2018 Feb 20;48(2):380-395.e6. (PMID: 29426702) J Anat. 2002 Jun;200(6):639-46. (PMID: 12162731) Nature. 2012 Feb 15;483(7390):479-83. (PMID: 22343889) Ann Neurol. 2012 Nov;72(5):766-78. (PMID: 23280793) Science. 2004 May 28;304(5675):1338-40. (PMID: 15060285) Nat Cell Biol. 2016 Dec;18(12):1336-1345. (PMID: 27820599) Dev Biol. 2007 Feb 1;302(1):356-66. (PMID: 17188262) EMBO Mol Med. 2013 Mar;5(3):384-96. (PMID: 23495140) Genes Dev. 2011 Dec 15;25(24):2594-609. (PMID: 22190458) Lancet Neurol. 2015 Oct;14(10):977-9. (PMID: 26376966) J Neurooncol. 2013 Aug;114(1):149-54. (PMID: 23780645) Clin Cancer Res. 2013 Sep 15;19(18):4951-60. (PMID: 23864165) Oncotarget. 2018 Feb 20;9(23):16462-16476. (PMID: 29662659) Cancer Res. 2006 Apr 15;66(8):3987-91. (PMID: 16618716) Nat Med. 2018 Aug;24(8):1192-1203. (PMID: 29988124) Nature. 2016 May 18;533(7604):493-498. (PMID: 27225120) Immunity. 2017 Feb 21;46(2):197-204. (PMID: 28228279) Cancer Immunol Res. 2013 Aug;1(2):112-22. (PMID: 24409449) Clin Cancer Res. 2014 Jan 1;20(1):187-98. (PMID: 24240114) J Clin Oncol. 2004 Jul 15;22(14):2865-72. (PMID: 15254054) Transl Oncol. 2009 May;2(2):89-95. (PMID: 19412424) Nature. 2013 Aug 22;500(7463):415-21. (PMID: 23945592) Cancer Discov. 2016 Feb;6(2):202-16. (PMID: 26645196) JAMA Oncol. 2016 Oct 01;2(10):1354-1360. (PMID: 27355489) N Engl J Med. 2010 Sep 30;363(14):1324-34. (PMID: 20879881) Nature. 2015 Feb 26;518(7540):547-51. (PMID: 25470051) Nat Neurosci. 2016 Jan;19(1):20-7. (PMID: 26713745) Cell Rep. 2016 Apr 26;15(4):857-865. (PMID: 27149842) Cancer Cell. 2006 Mar;9(3):157-73. (PMID: 16530701) Med Oncol. 2015 Jan;32(1):400. (PMID: 25433950) Cell. 2009 Jul 10;138(1):51-62. (PMID: 19576624) Clin Cancer Res. 2017 Oct 15;23(20):6279-6291. (PMID: 28754819) Nat Methods. 2013 Nov;10(11):1046-7. (PMID: 24037243) Neuro Oncol. 2013 Dec;15(12):1664-72. (PMID: 24084410) Cell Rep. 2016 Nov 22;17(9):2445-2459. (PMID: 27840052) Clin Neurol Neurosurg. 2011 Apr;113(3):224-9. (PMID: 21195542) Nat Cell Biol. 2013 Jul;15(7):807-17. (PMID: 23728425) Cancer Cell. 2016 Apr 11;29(4):508-522. (PMID: 27050100) Nat Neurosci. 2019 Jun;22(6):1021-1035. (PMID: 31061494) Science. 1999 Jun 18;284(5422):1994-8. (PMID: 10373119) Nat Neurosci. 2018 Sep;21(9):1209-1217. (PMID: 30150661) N Engl J Med. 2018 Jul 12;379(2):150-161. (PMID: 29943666) EBioMedicine. 2018 Feb;28:97-104. (PMID: 29396294) J Cell Biol. 2012 Feb 20;196(4):395-406. (PMID: 22351925) Nat Med. 2018 Jul;24(7):1024-1035. (PMID: 29892069) Cancer Res. 2017 May 1;77(9):2266-2278. (PMID: 28235764) N Engl J Med. 2015 Jun 25;372(26):2481-98. (PMID: 26061751) Lancet Oncol. 2016 Jul;17(7):976-983. (PMID: 27267608) Clin Cancer Res. 2016 Aug 15;22(16):4057-66. (PMID: 26994146) Science. 2017 Jul 28;357(6349):409-413. (PMID: 28596308) Nat Rev Cancer. 2016 Jul;16(7):431-46. (PMID: 27282249) Acta Neuropathol. 1999 Oct;98(4):349-54. (PMID: 10502039) Sci Rep. 2017 Mar 22;7:44792. (PMID: 28327577) Glia. 2005 Apr 15;50(2):132-44. (PMID: 15657938) Cell. 2014 Feb 27;156(5):1002-16. (PMID: 24581498) N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009) Neuro Oncol. 2017 Jun 1;19(6):796-807. (PMID: 28115578) J Exp Med. 2015 Jun 29;212(7):991-9. (PMID: 26077718) Cancer Treat Rev. 2016 Apr;45:38-45. (PMID: 26975020) J Clin Oncol. 2013 Jan 20;31(3):344-50. (PMID: 23071237) N Engl J Med. 2014 Feb 20;370(8):709-22. (PMID: 24552318) |
فهرسة مساهمة: | Keywords: brain cancer; brain metastasis; glioblastoma; glioma; immunotherapy; tumor microenvironment |
تواريخ الأحداث: | Date Created: 20191022 Date Completed: 20201030 Latest Revision: 20240720 |
رمز التحديث: | 20240720 |
مُعرف محوري في PubMed: | PMC6779728 |
DOI: | 10.3389/fimmu.2019.02294 |
PMID: | 31632393 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!